Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sirtex Collaboration with the National Cancer Centre of Singapore

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Researchers from SGH and NCCS will explore the potential of Carbon Cage Nanoparticles to develop a new generation of cancer therapies.

Sirtex Medical Limited has announced that it has signed a Master Research Collaboration Agreement with SingHealth.

Under this agreement researchers from Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) will explore the potential of a new technology known as Carbon Cage Nanoparticles to develop a new generation of cancer therapies.

Developed by the Australian National University, Carbon Cage Nanoparticles can safely deliver radioactive substances to specific cancer sites deep within the body.

The nanoparticles may even evade detection by patients’ immune systems, improving their ability to target specific cancers.

SingHealth’s team of leading medical scientists and physicians have been quick to recognize these unique properties and the many potential applications of this technology that may represent a breakthrough in the treatment of a range of different cancers.

The master agreement will comprise several research projects. The first will evaluate the technology’s use in the treatment of advanced ovarian cancer that has spread within the abdominal and pelvic cavities.

Ovarian cancer is a common cancer in women and has few or no symptoms in its early stages. As a result, most women are diagnosed late, when the disease has spread and prognosis is poor.

A variety of other gastro-intestinal, hepato-biliary and female genito-urinary cancers may potentially benefit from such a treatment approach.

Mr Gilman Wong, Chief Executive Officer, Sirtex said, “Over the past six years Sirtex has been working with the Australian National University to develop a leading position in nanoparticle IP that may be developed for the treatment of human cancers in areas of unmet clinical need. This Master Research Collaboration Agreement with SingHealth is a milestone in the development of Sirtex’s Carbon Cage Nanoparticle technology and brings together a leading group of physician scientists from the National Cancer Centre of Singapore with a strong track record of transitioning new technologies into the clinic.”

Professor Soo Khee Chee, Deputy Group CEO (Research and Education), SingHealth, and Director, NCCS said “Sirtex’s partnership with SingHealth is a clear testimony of our capability to provide high quality pre-clinical and translational research that can be used to develop new products. Collaborations with industry partners such as Sirtex provide new, cutting-edge technologies that allow us to offer our patients better treatment options, faster.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Triple-Action Therapy Patch Shows Promise
Patch that delivers drug, gene, and light-based therapy to tumor sites shows promising results in mice.
Cancer Gene-Drug Combinations Ripe for Precision Medicine
The study aims to expand the number of cancer gene mutations that can be paired with a precision therapy.
Exploiting Malaria’s Achilles’ Heel
Researchers have uncovered an Achilles' heel in malaria's anti-drug treatment arsenal that could lead to a disease cure.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Cancer Related Immune Response Genes Uncovered
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!